Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

23andMe

Biotech & Life Sciences · Sunnyvale, United States · Founded 2006 Unicorn

A public taster of the full Dealroom platform — request a demo to explore live financials, founders, funding history, and market intelligence.

Valuation
$150M
Market cap · 2026
Revenue
$190M
Latest reported FY

Helping people access, understand, and benefit from the human genome

Investors

18 investors on 23andMe's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 5 investors entered at this stage
Genentech
Mohr Davidow Ventures
Stephens Investment Management
NEA
Alphabet | Google
Series B+ 13 investors entered at this stage
Xfund
Future Planet Capital
GSK
Illumina
Sergey Brin
Anne Wojcicki
NewView Capital
Casdin Capital
Yuri Milner
MPM BioImpact
Johnson & Johnson Development Corporation
Fidelity Investments
Sequoia

Global footprint

Where 23andMe has talent and traffic

AI talent share
2.5% of workforce is AI talent
(14 of 560 staff)
Core AI40.71%
Other AI101.79%
Non-AI workforce54697.5%
Workforce by country
13 countries with
team presence
🇺🇸 United States95.3%
🇨🇳 China0.8%
🇧🇩 Bangladesh0.4%
🇧🇷 Brazil0.4%
🇦🇷 Argentina0.4%
Top 5 of 13 shown
Web traffic by country
4.8M monthly visits
across markets
🇺🇸 United States76.1%
🇬🇧 United Kingdom6.1%
🇨🇦 Canada5.7%
🇦🇺 Australia0.5%
🇻🇳 Vietnam0.5%
Top 5 markets shown

Patent intelligence

$52M patent portfolio · 50 active families

Estimated portfolio value
$52M
34.4% of market cap · 9.7× smaller than top peer Insulet ($502M)
50 active patent families
Where 23andMe innovates Data miningData scienceComputational biologySoftwareBioinformatics

Where 23andMe concentrates vs peers

Each axis is a top-10 topic across 23andMe and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

23andMe's 4 investments and acquisitions.

Every disclosed deal where 23andMe appeared as a backer or acquirer, 2012–2021. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

4 deals across 23andMe's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where 23andMe deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        23andMe's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        4 of 4 deals

        Sentiment on X

        What X is saying about 23andMe

        An AI-synthesized read of the highest-engagement posts about 23andMe on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See 23andMe on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.